An observational study in Mild Cognitive Impairment (MCI), Dementia Alzheimer Type and Chronic Pain, sponsored by Korea University. Recruiting at 1 site in South Korea. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Korea University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of — 17 open to participants now, 24 under way, 5 of them phase 3. Cognitive Dysfunction · Korea, Republic of.
Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, this one is the 8th largest by planned enrollment of the 17 observational ones that give a count, is one of 13 that started in 2025, is one of 17 observational ones, reaches primary completion later than 15 of the 23 other live ones, and was the 72nd registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →17 of the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, United States, Japan and 1 more country
Ages 55–85
Deepsonbio · Sites in Korea, Republic of
Ages 55–90
NeuroBiogen Co., Ltd · Sites in Korea, Republic of
Ages 50–85
Bristol-Myers Squibb · Sites in Korea, Republic of, United States, Argentina and 16 more countries
Ages 60–85
Hoffmann-La Roche · Sites in Korea, Republic of, United States, Argentina and 12 more countries
Ages 50–90
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 94 across the 57 interventional studies, 163 across the 17 observational. Of the 34 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 74 have an industry lead sponsor. The 10 most frequent:
Korea University is the lead sponsor of 64 studies on the registry; 7 are open to participants now.
Korea University has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
10 of the studies in Cognitive Dysfunction with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07239310DeepsonbioNeuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease | 2026-12 |
| NCT07334366Pusan National University Yangsan HospitalBroccoli Sprout Extract for Cognitive Function | 2026-12-30 |
| NCT07011680Pusan National University Yangsan HospitalPhospholipid-rich Dairy Extract for Cognitive Function | 2026-12-30 |
| NCT06786676Amyloid Solution IncA Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn how daily emotional stress affects cognitive function and inflammation in community-dwelling older adults aged 60 and older in Seoul, Republic of Korea. The main questions it aims to answer are:
Does daily psychological stress measured in real-time affect short-term and long-term cognitive function in older adults? Do pro-inflammatory cytokines (such as CRP, IL-6, IL-10, and TNF-α) mediate the relationship between emotional stress and cognitive decline? How do social support and social isolation influence cognitive function and inflammatory biomarkers over time?
Participants will:
Complete baseline surveys assessing depression, cognitive function, and personal characteristics Use a smartphone app to answer brief surveys about their emotions, cognitive performance, and social interactions 1-6 times daily for two weeks Wear a Galaxy Watch to track sleep quality, heart rate, and physical activity Provide blood samples for inflammatory biomarker analysis Return for follow-up assessments at 6 months and 1 year
This study is part of an international collaboration to establish a Korean cohort comparable to the U.S. Einstein Aging Study, with the aim of developing culturally tailored dementia prevention strategies.
A. Final Goal
The principal investigator's research team at Korea University's Department of Public Health Sciences and the team led by Professors Jennifer Graham-Engeland and Christopher Engeland from Penn State University (co-leaders of the Einstein Aging Study under NIH P01), aims to establish a protocol for the domestic cohort of the Einstein Study of Aging and conduct cross-national comparative research. The specific objectives are:
B. Research Design and Overview
Korean Cohort Design that is comparable with the Einstein Aging Study
Participant Recruitment and Incentives
Following IRB approval, socially vulnerable older adults (recipients of social welfare support due to economic poverty and social isolation) will be recruited through the Seongbuk Senior Welfare Center in Seoul, Republic of Korea. Training sessions on smartphone EMA will be provided as part of smartphone classes. Participants will receive tokens of appreciation and dementia prevention seminar opportunities.
1) Participant Selection Criteria
Exclusion: Individuals diagnosed with dementia or those with sensory, cognitive, or physical impairments that hinder survey and EMA participation.
2) Two-Week EMA Protocol
EMA minimizes recall and response biases, enabling precise quantification of intra-individual changes. Custom apps incorporating voice-assisted surveys and integration with Galaxy watch for sleep quality, heart rate variability, and physical activity data will be used, alongside cognitive tasks from the EAS protocol.
3) Pro-Inflammatory Cytokine Signaling Measurement
C. Expected Impact and Merit to the society
Utilization Plans
① Policy and Program Development:
Insights from the study's findings on the bio-psycho-social mechanisms of cognitive decline in aging can inform policies and interventions for dementia prevention and management in a rapidly aging society.
Anticipated Merits
Scientific and Technological Merits:
The study will provide a foundation for innovative elderly care models, linking digital sensing technologies with cognitive health monitoring. It could support the development of remote dementia prevention and management services for community and residential care settings.
This study targets community-dwelling older adults aged 60 and older in Seoul, Republic of Korea. Participants are recruited from the Seongbuk Senior Welfare Center and Gangbuk Municipal Senior Welfare Center.
Seongbuk-gu and Gangbuk-gu are districts with higher proportions of older adults and elevated chronic disease rates compared to other areas in Seoul, making them regions of interest for aging research.
The study population includes older adults living independently in the community who utilize local senior welfare center services. By recruiting from these districts, the study aims to generate evidence for developing effective dementia prevention strategies applicable to community-based settings in Korea.
Participants must be Samsung Galaxy smartphone users with sufficient cognitive ability to engage with ecological momentary assessment (EMA) protocols. Exclusions: dementia diagnosis, severe sensory impairments, or health conditions preventing participation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Community-dwelling older adults aged 60 and older recruited from the Seongbuk Senior Welfare Center in Seoul, Republic of Korea. Inclusion criteria: Adults aged 60 or older residing in Korea; Samsung Galaxy smartphone users; MMSE score of 21 or above; those not meeting cognitive criteria may participate with legal guardian consent. Exclusion criteria: Dementia diagnosis at baseline; severe visual or hearing impairments; illiteracy; less than 80% compliance with 2-day preliminary EMA protocol; alcohol or substance abuse; inability to ambulate or psychiatric conditions preventing participation; current cancer treatment or chemotherapy within past 6 months. This is a prospective observational cohort. Participants complete baseline assessments, then a two-week EMA period using a smartphone app for daily emotions, cognition, and social interactions. Galaxy Watch monitors sleep, heart rate, and activity. Blood samples collected for inflammatory biomarkers. Follow-ups at 6 and 12 months.
Incident MCI and Dementia Diagnosis
Incident mild cognitive impairment (MCI) and dementia diagnoses will be identified through clinical diagnosis during the study periods and linkage with the National Health Insurance Service (NHIS) database in Korea. This administrative data linkage enables long-term tracking of cognitive outcomes beyond the active study period.
Time frame: baseline, 6-month, 1-year, 5-year and 10-year follow-up
SNSB-2 Composite Score
Composite score from the Seoul Neuropsychological Screening Battery-2 (SNSB-2), a standardized neuropsychological assessment covering attention, language, visuospatial function, memory, and executive function domains (Standardized composite z-score).
Time frame: Baseline and 12 months
Wechsler Memory Scale Score
Memory function assessed using the Wechsler Memory Scale (Index score (points)).
Time frame: Baseline, 6 months, and 12 months
Block Design Subtest Score
Visuospatial constructional ability assessed using the Block Design subtest from the Wechsler Adult Intelligence Scale (WAIS) in Scaled score (points).
Time frame: Baseline, 6 months, and 12 months
EMA Daily Cognitive Task Performance
Daily cognitive performance measured via smartphone-based ecological momentary assessment (EMA) using the Mobile Monitoring of Cognitive Change (M2C2) platform during the 2-week intensive period. Performance is assessed as accuracy (proportion correct) and reaction time on cognitive tasks.
Time frame: Daily during 2-week EMA period at baseline, 6 months, and 12 months
Plasma Phosphorylated Tau (p-tau) Level
Plasma concentration of phosphorylated tau, a biomarker of tau-related neurodegeneration in Alzheimer's disease.
Time frame: Baseline, 6 months, and 12 months
Pro-Inflammatory Cytokine Composite Score
Serum levels of pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-10 (IL-10), and tumor necrosis factor-alpha (TNF-α) will be measured using a multiplex ELISA. A cytokine composite score will be calculated using the factor analysis.
Time frame: Baseline, 6 months, and 12 months
Plasma Amyloid Beta (Aβ) Level
Plasma concentration of amyloid beta, a biomarker associated with Alzheimer's disease neuropathology (pg/mL).
Time frame: Baseline, 6 months, and 12 months
ApoE Genotype
Apolipoprotein E (ApoE) genetic variation determined by DNA analysis. Participants will be classified as ApoE ε4 carriers or non-carriers.
Time frame: Baseline
EMA Daily Negative Affect
Daily negative emotional states measured via smartphone-based EMA surveys administered 1-6 times per day during the 2-week intensive period (0-100 scale).
Time frame: Daily during 2-week EMA period at baseline, 6 months, and 12 months
EMA Daily Positive Affect
Daily positive emotional states measured via smartphone-based EMA surveys administered 1-6 times per day during the 2-week intensive period. The scores are assessed by a mean score (0-100 scale).
Time frame: Daily during 2-week EMA period at baseline, 6 months, and 12 months
Depressive Symptoms
Depressive symptoms assessed using the Patient Health Questionnaire-9 (PHQ-9) at each follow-up visit. Yes/No coding will be used to assess reports of depressive symptoms.
Time frame: Baseline, 6 months, and 12 months
EMA Daily Social Interaction Frequency
Frequency of daily social interactions measured via smartphone-based EMA surveys during the 2-week intensive period. Unit of Measure: Number of interactions per day
Time frame: Daily during 2-week EMA period at baseline, 6 months, and 12 months
Daily Sleep Quality
Sleep quality continuously monitored using Galaxy Watch during the 2-week EMA period, including total sleep time and sleep efficiency.
Time frame: Continuous during 2-week EMA period at baseline, 6 months, and 12 months
Daily Heart Rate Variability (HRV)
Heart rate variability continuously monitored using Galaxy Watch during the 2-week EMA period.
Time frame: Continuous during 2-week EMA period at baseline, 6 months, and 12 months
Daily Physical Activity Level
Physical activity continuously monitored using Galaxy Watch accelerometer during the 2-week EMA period (steps per day).
Time frame: Continuous during 2-week EMA period at baseline, 6 months, and 12 months
Serum C-Reactive Protein (CRP) Level
High-sensitivity C-reactive protein measured from serum samples as a marker of systemic inflammation (mg/L).
Time frame: Baseline, 6 months, and 12 months
Serum Cortisol Level
Cortisol level measured from serum samples using enzyme-linked immunosorbent assay (ELISA) (nmol/L).
Time frame: Baseline and 12 months
Plan to share: No — Individual participant data (IPD) will not be shared with other researchers. According to the informed consent approved by the Institutional Review Board (IRB), participants agreed that their data would only be used by the authorized research team. Sharing IPD with external researchers was not included in the consent process, and doing so would violate the terms of consent and participant privacy protections.
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.
Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 24 months is below that.
Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Korea University